Five Dow Powerhouses Trading Below 2024 Highs: Are They Hidden Gems or Value Traps in 2026?

The Setup: Blue-Chip Selloff Amid Economic Headwinds

While the Dow Jones Industrial Average has climbed over 14% year-to-date through December 26, 2025, five of its most recognizable constituents tell a different story. Home Depot, Procter & Gamble, Nike, Salesforce, and UnitedHealth Group have each surrendered more than 10% of their value in 2025. Beyond the headlines lies an intriguing opportunity for contrarian investors — those willing to swim against the current when fundamentals remain intact.

The common thread? Macro pressures, sector headwinds, and temporary operational challenges have pushed these household names into unfavorable territory. But as experienced value hunters know, dislocation between price and intrinsic worth often creates the best long-term entry points.

Consumer Weakness: The Hidden Tax on Home Improvement and Staples

Home Depot and Procter & Gamble both face the same structural headwind: consumers tightening their belts. Despite equity market euphoria at record highs, household sentiment remains fragile. Rising living expenses, persistent inflation concerns, tariff uncertainties, and labor market jitters have dampened discretionary spending.

For Home Depot, the impact is particularly acute. Major home renovation projects are getting postponed, and the housing market remains sluggish. Yet the company hasn’t been idle — strategic acquisitions and store expansion investments position it for the next upturn. Trading at a forward P/E of just 24.1x and offering a 2.7% dividend yield, the stock looks reasonably priced for patient capital willing to wait for consumer confidence to return.

Procter & Gamble faces similar headwinds, though from a different angle. Consumer staples as a sector have lagged the S&P 500 by nearly 18 percentage points in 2025 — a stark reversal from typical defensive outperformance. Margin pressures from tariffs and supply chain disruptions have been relentless. However, P&G’s diversified product portfolio, international revenue streams, and elite operational execution have allowed it to maintain pricing power and margin resilience. With 69 consecutive years of dividend increases and a 2.9% yield, the company continues to deliver for income-focused investors, even if near-term growth remains tepid.

Nike’s Comeback Narrative: Tariffs, China, and Brand Reinvention

Nike has suffered four consecutive years of stock price declines — a humbling streak for the world’s most recognizable athletic brand. The culprits are familiar: tariff headwinds compressing gross margins, a sharp slowdown in China, and North American consumer caution.

But there’s more to the story than macroeconomic turbulence. Nike’s competitive moat has narrowed. Innovation cycles have faltered relative to rivals, and consumer preferences are fragmenting across more brands than ever before. The response? Nike is returning to what built its empire: compelling storytelling and authentic product innovation rather than relying on distribution convenience alone.

The pivot requires time, but management has made tangible progress integrating wholesale partners while preserving direct-to-consumer strength. Additionally, recent enthusiasm from high-profile stakeholders — including a notable increase in ownership by Apple’s CEO — suggests insider confidence in the turnaround thesis. At a 2.7% dividend yield and with the stock under pressure, 2026 could reward believers in the brand’s staying power.

Salesforce: The AI Repricing Story

Salesforce has been caught in the broader software selloff as investors reassess the subscription software model under an artificial intelligence paradigm. The core fear: if AI enables users to accomplish more with fewer licenses, enterprise spending on SaaS could deflate.

This concern isn’t baseless, but it oversimplifies Salesforce’s positioning. The company is fighting back with Agentforce — AI-powered virtual assistants that accelerate workflows and boost productivity. The pricing model involves per-user add-ons, which could offset subscription pressure if adoption scales. Critically, Salesforce already boasts deep customer entrenchment across its ecosystem (Slack, Tableau, MuleSoft), creating formidable switching costs.

Growth may have decelerated, but Salesforce remains profitable with healthy margins. At 22.6x forward earnings — a steep discount to historical norms — much of the downside risk appears priced in. Combined with a modest 0.6% dividend, the risk-reward setup favors contrarian investors with a multi-year horizon.

UnitedHealth: The Turnaround Play

The worst performer in the Dow cohort, UnitedHealth has lost roughly one-third of its value — a staggering decline driven by a perfect storm of rising medical utilization costs, Medicare Advantage pricing miscalculations, and an unwelcome Department of Justice criminal investigation.

Yet this is precisely where contrarian investing logic applies: when consensus assumes the worst is still coming, the opposite often holds true. UnitedHealth’s core business model remains powerful. The UnitedHealthcare segment collects premiums across Medicare, Medicaid, employer, and individual plans, while Optum delivers health services — a combination that generates dependable cash flows and supports progressive dividend growth when operating normally.

Management is already responding by raising premiums to reflect higher medical cost inflation, a move expected to bolster results in 2026. Valued at just 20.3x forward earnings with a 2.7% dividend yield, UnitedHealth represents a high-conviction play for value investors betting on mean reversion and operational stability restoration.

The Contrarian’s Checklist

All five stocks share a critical characteristic: they’ve been heavily sold down despite remaining operationally sound. Tariffs, consumer caution, competitive challenges, and temporary investigations have clouded near-term visibility, but the long-term thesis for each remains intact.

For investors with conviction in fundamental recovery and the patience to ignore short-term volatility, 2026 could be the year these contrarian bets prove their worth.